Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Catabasis Pharma (CATB)

Catabasis Pharma (CATB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 120,984
  • Shares Outstanding, K 17,897
  • Annual Sales, $ 0 K
  • Annual Income, $ -26,290 K
  • 60-Month Beta 1.77
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.22

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.46
  • Number of Estimates 2
  • High Estimate -0.45
  • Low Estimate -0.46
  • Prior Year -0.62
  • Growth Rate Est. (year over year) +25.81%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.15 +8.62%
on 06/11/20
7.73 -13.58%
on 06/25/20
+0.33 (+5.20%)
since 06/08/20
3-Month
4.35 +53.56%
on 04/09/20
7.73 -13.58%
on 06/25/20
+2.27 (+51.47%)
since 04/08/20
52-Week
2.74 +143.80%
on 03/18/20
7.81 -14.47%
on 07/11/19
-0.76 (-10.22%)
since 07/08/19

Most Recent Stories

More News
Catabasis Joins Russell 3000(R) Index

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, announced today that it has joined the broad-market Russell 3000(R) Index at the conclusion of the 2020 Russell...

CATB : 6.68 (-1.18%)
Catabasis Pharmaceuticals Names Ben Harshbarger Senior Vice President, General Counsel

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, announced today that it has named Ben Harshbarger as Senior Vice President, General Counsel. Mr. Harshbarger brings...

CATB : 6.68 (-1.18%)
Catabasis Pharmaceuticals Reports First Quarter 2020 Financial Results and Reviews Business Progress

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today reported financial results for the first quarter ended March 31, 2020 and reviewed recent business progress....

CATB : 6.68 (-1.18%)
Catabasis Pharmaceuticals Presents Edasalonexent, a Potential Foundational Therapy for Duchenne Muscular Dystrophy

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today shared information on the edasalonexent program in Phase 3 development for the treatment of Duchenne muscular...

CATB : 6.68 (-1.18%)
Catabasis Pharmaceuticals to Report First Quarter 2020 Financial Results on Tuesday, May 12th

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will report first quarter 2020 financial results after the Nasdaq Global Market close on Tuesday, May 12, 2020....

CATB : 6.68 (-1.18%)
Catabasis Pharmaceuticals to Present at 2020 Muscular Dystrophy Association Virtual Poster Session

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it will present information on the edasalonexent program in Phase 3 development for the treatment...

CATB : 6.68 (-1.18%)
Catabasis Pharmaceuticals to Present at the Upcoming 2020 Solebury Trout Virtual Investor Conference

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, plans to present a corporate overview and...

CATB : 6.68 (-1.18%)
Solebury Trout Announces Virtual Conference Series with Presentations from Life Science Companies

NEW YORK, NY / ACCESSWIRE / March 24, 2020 / Solebury Trout, a boutique investor relations and corporate communications firm, announced today that it will be hosting a Virtual Conference Series on March...

AFMD : 4.58 (+4.33%)
APM : 3.45 (+1.47%)
CATB : 6.68 (-1.18%)
EPIX : 6.20 (+1.64%)
EVFM : 3.30 (+4.10%)
PIRS : 3.06 (-7.83%)
SLGL : 8.37 (-2.33%)
Catabasis Pharmaceuticals to Present During the Muscular Dystrophy Association Virtual Clinical Trials Session

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it will present information on the edasalonexent program in Phase 3 development for the treatment...

CATB : 6.68 (-1.18%)
Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Reviews Business Progress

-- Conference Call and Webcast Today at 8:30am ET --

CATB : 6.68 (-1.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade CATB with:

Business Summary

Catabasis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of therapeutics for treatment of inflammatory, immunological and metabolic diseases. Its product development pipeline includes CAT-1004, CAT-2000 series including CAT-2054...

See More

Key Turning Points

2nd Resistance Point 7.07
1st Resistance Point 6.87
Last Price 6.68
1st Support Level 6.50
2nd Support Level 6.33

See More

52-Week High 7.81
Last Price 6.68
Fibonacci 61.8% 5.87
Fibonacci 50% 5.28
Fibonacci 38.2% 4.68
52-Week Low 2.74

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar